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Interleukin 2 Treatment Does Not Modify Hepatitis B or C Replication in Human Immunodeficiency
Virus–Infected Patients: Results From a Randomized Control Trial
To the Editor:
Because of common routes of transmission, human immuno-
deficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C
virus (HCV) infections are often found simultaneously in the same
patient. Clinical consequences of such coinfection may lead rap-
idly to the development of severe liver-related complications.1 We
investigated the effects of interleukin-2 (IL-2) treatment in HIV
patients coinfected with HBV, HCV, or both hepatitis viruses.
Seventy-two HIV-infected patients were enrolled in a 6-month
randomized controlled study (ANRS 082, ILSTIM) comparing
subcutaneous injection of IL-2 (4.5 million international units
[IU], twice daily, 5 days a week, every 6 weeks) in addition to their
prior highly active antiretroviral treatment (HAART) (IL-2 group)
versus HAART alone (control group).2 Main criteria for inclusion
were a controlled HIV infection under HAART containing a pro-
tease inhibitor for at least 6 months, with HIV viral loads below
1,000 copies/mL for at least 3 months, and CD4 cell counts be-
tween 25 and 200/mm3 since the beginning of the protease inhib-
itor treatment. All patients who completed their treatment (n 5
69) were tested for the presence of hepatitis B surface antigen and
specific HCV antibodies (Axsym, Abbott, France). Viremia for
each virus was determined at the time of inclusion and after IL-2
treatment completion (24 weeks). Nine patients (13%) tested pos-
itive for HBV, 12 (17.4%) for HCV, and 3 (4.3%) patients were
HBV and HCV coinfected (Table 1). At the time of inclusion,
HCV-positive patients had significantly higher alanine transami-
nase (ALT) levels than HCV-negative patients (median 76.5 vs. 24
IU/L, P 5 .0005), whereas no ALT difference was seen for HBV-
infected patients. During IL-2 treatment, no significant change in
ALT levels was observed in HBV-coinfected patients; by contrast,
an important but not statistically significant drop (P 5 .089) was
noticed for HCV-infected subjects. Interestingly, we did not no-
tice any significant change in HBV or HCV viral load under IL-2
treatment compared with the control group.
The immunologic component in chronic viral hepatitis is not
fully understood and seems to involve a balance between the host
immune response and the virus itself. Thus, because of the pleio-
tropic effects of IL-2, one may speculate that an IL-2–induced shift
towards a more potent immune response could help to clear viral
infections. Very few trials have studied the effects of IL-2 on viral
hepatitis, and comparison of these trials are made difficult because
of the different IL-2 dosages and schedules used. However, 3 recent
reports on a limited number of HIV-coinfected patients have
looked at the effects of IL-2 on hepatitis virus replication.3-5 While
Uberti-Foppa et al. found a significant decrease in HCV viral loads
and Gianotti et al. described clearance of hepatitis B surface anti-
gen in a single patient, our data as well as those from Hengge et al.
do not support any effect of IL-2 treatment on either HCV or
HBV replication.
In conclusion, despite a significant increase in CD4 cell count
in the IL-2–treated group compared with the control group pa-
tients (median increase in CD4: 65 vs. 18/mm3, P , 1026), IL-2
treatment did not modify hepatitis viruses replication.2 The de-
crease in transaminase levels in HCV-infected subjects may indi-
cate that such treatment could affect liver disease progression; how-
ever, a more careful histologic and biochemical monitoring would












Table 1. Main Biological Parameters (median, range) at Inclusion and 24 Weeks After IL-2 Treatment
HBV Positive HCV Positive HBV and HCV Positive
Control IL-2 Control IL-2 Control IL-2
n (%) 3 6 7 5 2 1
HBV viral load* at inclusion Negative 5 (2.9-8.0) NA NA Negative Negative
HBV viral load* at week 24 Negative 4.9 (2.6-8.6) NA NA Negative Negative
HCV viral load* at inclusion NA NA 7.3 (6.6-8.0) 7.3 (6-8.3) 5.4/Negative Negative
HCV viral load* at week 24 NA NA 7.4 (6.8-7.9) 7.3 (6.4-8.4) 7.6/Negative NAV
ALT† level at inclusion (IU/L) 14 (8-23) 33.5 (12-112) 54 (8-100) 115 (29-154) 78/125 25
ALT† level at Week 24 (IU/L) 11 (7-15) 35 (8-56) 49 (16-81) 45.5 (5-80) 81/115 12
CD4 count at inclusion
(cells/mm3) 108 (93-110) 163 (97-195) 157 (63-190) 161 (106-187) 174/124 94
CD4 count at week 24
(cells/mm3) 127 (102-178) 251 (180-322) 160 (84-198) 203 (190-222) 281/146 208
Abbreviations: NA, not applicable; NAV, not available.
*Viral load medians (range) are expressed as Log10 copies/mL for HBV (Monitor-ROCHE) and as Log10 Equivalent genome/mL for HCV (bDNA2.0-BAYER).
†Normal value for ALT is below 35 IU/L.
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The 4,977–Base Pair Common Deletion of Mitochondrial DNA Is Not Associated With Steatosis
in Chronic Hepatitis C Patients
To the Editor:
Mitochondrial DNA (mtDNA) deletions have been detected in
the liver of patients with alcohol-, drug-, and metabolic-related
steatosis and may play a role in the pathogenesis of liver disease.1 At
the 51st Annual Meeting of the American Association for the
Study of Liver Diseases,2 a 4,977-bp deletion (common deletion)
of mtDNA was reported to be associated with the steatosis ob-
served in chronic hepatitis C. We assessed the prevalence of the
mtDNA common deletion in the liver of chronic hepatitis C pa-
tients and compared it with the presence and severity of liver ste-
atosis. Two groups of chronic hepatitis B patients and healthy
adults served as controls.
A liver biopsy was obtained from 69 patients with histologically
confirmed chronic hepatitis C. There were 46 men and 23 women.
The median age was 46 years (range, 30-70). Eighteen patients had
cirrhosis and 23 were infected with HCV genotype 3, which has
been associated with liver steatosis.3 All lacked factors (other than
hepatitis C virus) associated with a fatty liver, i.e., chronic alcohol
consumption, a body mass index (weight [kg]/height2 [m2])
greater than 26, decompensated diabetes, or the administration of
hepatotoxic drugs. Macrovesicular steatosis was absent or minimal
(,1% of hepatocytes) in 36 patients, mild (,30% hepatocytes) in
21, moderate (between 30% and 60% of hepatocytes) in 7, and
severe (.60% of hepatocytes) in 5. Controls included 15 liver
biopsy specimens from chronic hepatitis B patients and 8 normal
adult livers taken at surgery (cholecystectomy or resection of liver
metastasis of extrahepatic malignancies). None of the controls had
steatosis.
A portion of each liver sample, adjacent to that being histolog-
ically evaluated, was snap-frozen for total liver DNA extraction.3
To confirm the quality and quantity of extracted DNA, a first
polymerase chain reaction (PCR) was performed with primers C1
(nt 9911-9932) and C2 (nt 11873-11851) (Fig. 1A).4,5 To dis-
criminate between deleted and undeleted mtDNA, we used a com-
bination of PCR strategies. Two couples of primers, A-A1 and
B-B15 or A-A1 and MT1-MT36 were chosen to perform a nested
PCR (Fig. 1A). Primers flanked the 13-bp direct repeat associated
with the mtDNA common deletion. Long Template Taq polymer-
ase was purchased from Roche (Basel, Switzerland). The 6-kb
product of undeleted mtDNA was expected after 3 minutes of
Fig. 1. (A and B) Map showing the position of the different primers used in
the present work with respect to the mtDNA common deletion, located between
base positions 8482 and 13459. Wild-type (A) and 4977-bp deleted form (B)
of mtDNA. The circular mtDNA molecule is here represented as linearized for
reasons of simplicity. (C) PCR products from total liver DNA using mtDNA-specific
primers. Lanes 2 and 4, molecular size markers (1 kb DNA ladder, Promega,
Madison, WI). Wild-type, undeleted mtDNA give rise to 2-kb (lane 1) and 6-kb
(lane 3) PCR products using, respectively, primers C1-C2 and B-B1 (the latter
ones with a prolonged elongation time; please refer to text for explanations).
When the mtDNA presents the common deletion, primers MT1-MT3 yield a
360-bp product using a short elongation time (lane 5).
HEPATOLOGY, Vol. 35, No. 1, 2002 CORRESPONDENCE 239
extension at 72°C for 30 cycles in both rounds of PCR. To selec-
tively amplify the deleted form we used a shorter time of elongation
(30 seconds at 72°C for 30 cycles).6 The two PCR procedures
yielded a product, respectively, of 770 or 360 nt, depending on the
use of primers B-B1 or MT1-MT3 during the nested PCR.
PCR product(s) having a size compatible with the mtDNA
common deletion were detected in 62 of 69 (91%) chronic hepa-
titis C patients (30 with steatosis) and in all controls (Fig. 1b). The
mean age of the 62 chronic hepatitis C patients with the deletion
was comparable with that of patients without (50 6 7.3 years vs.
47 6 9.5 years, P 5 .32). The presence of the common deletion
was not associated with gender, HCV genotype, staging of liver
disease, or presence and severity of steatosis.
The high prevalence of the 4,977-bp mtDNA common dele-
tion found in our patients confirms its frequent detection in vari-
ous tissues from individuals over 20 years of age.7 However, we
failed to associate the occurrence of the mutation with the presence
of steatosis. The variable clinical presentation observed with this
mtDNA mutation may depend on the number of mutated
mtDNA molecules per cell and on its energy requirements.8 The
random segregation of mitochondria at the time of cell division
results in an mtDNA heteroplasmy. Intracellular mixtures of
mtDNA characterized by a high ratio of deleted versus wild-type
mtDNA are likely to bring about a decline of cellular energy ca-
pacities. Thus, heteroplasmy and the tissue specific energy thresh-
old are important disease determinants and should be taken into
account when considering the possible pathogenicity of an
mtDNA mutation. Whether the presence of liver steatosis depends
on the number of mutated mtDNA molecules per hepatocyte,
rather than on their occurrence, remains to be established by ap-
propriate quantitative assays.8 Thus, the lack of association with
steatosis may be caused by the failure to identify different ratios of
deleted versus wild-type mtDNA using a qualitative PCR.
We conclude that, based on a sensitive qualitative PCR screen-
ing, the common deletion of mtDNA is highly prevalent in the
liver of patients with hepatitis C virus, independent of histology. In
particular, we found no association with the occurrence and sever-
ity of liver steatosis.
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HDL Receptor SR-BI and Cholesterol Gallstones
To the Editor:
We read with great interest the recent report of Fuchs et al.1
on the up-regulation of hepatic scavenger receptor class B type
I (SR-BI) and caveolin-1 expressions associated with biliary
cholesterol hypersecretion and gallstone formation in gallstone-
susceptible C57L mice compared with resistant AKR mice.
While SR-BI is a functionally relevant HDL receptor for reverse
cholesterol transport,2 caveolin-1 appears to be important for
intracellular cholesterol trafficking.3 Thus, the study of Fuchs et
al.1 is consistent with a potential role of these cholesterol trans-
port proteins in the molecular pathogenesis of murine choles-
terol gallstone formation.
However, we would like to point out that similar studies per-
formed independently by our two groups do not agree with or
support the conclusions obtained by Fuchs et al.1 First, we ob-
served that on chow, there were no differences in hepatic SR-BI
protein expression between C57L and AKR mice. Furthermore,
feeding a lithogenic diet (1% cholesterol, 0.5% cholic acid, and
15% dietary fat) did not induce a significant alteration in hepatic
SR-BI levels in these mice (Rigotti et al. and Wang et al., unpub-
lished observations).
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Second, using gallstone-susceptible C57BL/6 mice,4 we studied
hepatic SR-BI and caveolin-1 protein expression during the feed-
ing of a lithogenic diet from Harlan Teklad. Amigo et al.5 found
that biliary cholesterol hypersecretion during gallstone formation
in these mice was associated with a decrease in plasma HDL cho-
lesterol. However, these alterations in HDL cholesterol concentra-
tions and biliary cholesterol secretion rates induced by the litho-
genic diet in C57BL/6 mice did not correlate with any changes in
hepatic SR-BI protein expression.6 Furthermore, we did not detect
significant up-regulation of caveolin-1 protein levels in the liver of
C57BL/6 mice fed the lithogenic diet compared with chow
(Miquel et al., unpublished observations).
Third, one of us has addressed more directly the potential rel-
evance of SR-BI expression for gallstone formation in mice during
feeding of a lithogenic diet. Wang et al.7 studied SR-BI att mice
with a partial deficiency (;50%) of hepatic SR-BI expression in-
duced by a dysfunctional mutation in the Sr-bi promoter. This
study found that decreased SR-BI expression in gallstone-suscep-
tible SR-BI att mice reduced biliary cholesterol secretion by 37%
on chow and 10% on the lithogenic diet and modestly, but not
significantly, decreased susceptibility to cholesterol gallstone for-
mation. Mardones et al.6 have also found that knockout of SR-BI
gene decreased biliary cholesterol secretion by ;55% in chow-fed
mice. Taken together, these results6,7 strongly suggest that on
chow, SR-BI is a major receptor regulating biliary cholesterol con-
centrations, however, it is much less relevant for controlling biliary
cholesterol hypersecretion derived from intestinal chylomicrons
during murine cholesterol gallstone formation on a lithogenic
diet.5,7
Despite the discrepancy between our results and the data of
Fuchs et al.,1 SR-BI is still likely to be a candidate gene to be
involved in gallstone formation due to increased HDL-mediated
reverse cholesterol transport. We await further studies that support
this hypothesis. If so, SR-BI may be an interesting drug target for
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Reply:
We appreciate the comments of Rigotti et al. on our recently
published report1 on the hepatic up-regulation of SR-BI during
cholesterol gallstone formation in C57L but not AKR mice. De-
spite interindividual variations in hepatic SR-BI expression, we
measured increased SR-BI protein levels in all C57L mice fed the
lithogenic diet. Contrary to our findings and employing AKR and
C57L mouse strains, their preliminary experiments did not show
significant alterations in the expressions of SR-BI protein in liver.
It is difficult to comment on these discrepancies, especially because
we do not know whether experimental or methodological differ-
ences exist between our investigations and those performed in the
laboratories of Drs. Rigotti and Wang.
Earlier studies using inbred mice2-5 showed variations in gall-
stone susceptibility in response to a lithogenic diet. Whereas gall-
stone prevalence was high in C57L/J mice, the closely related but
not genetically identical C57BL/6 strain was notable for an inter-
mediate prevalence. Subsequent genetic studies showed that this
most likely is related to different Lith genes in these 2 inbred mouse
strains.6 Thus, it is not surprising that C57BL/6 mice apparently
do not up-regulate hepatic protein expression of SR-BI and caveo-
lin-1 (Miquel et al., unpublished observations). Indeed, our own
preliminary results (Fuchs et al., unpublished observations) with
3-month-old male C57BL/6 mice also found no significant
changes in SR-BI protein expression when the animals were chal-
lenged with a commercially obtained lithogenic diet from Harlan
Teklad. Instead, these findings support a complex genetic regula-
tion of HDL cholesterol metabolism,7-9 which does not depend
only on SR-BI expression.
The interesting preliminary findings of Wang et al.10 obtained
in mice with a partial deficiency of hepatic SR-BI protein ex-
pression do not necessarily contrast our finding of hepatic up-
regulation of SR-BI during cholesterol gallstone formation. It is
likely that the genetic manipulation in these mice induced the
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expression of other genes involved in cholesterol and lipoprotein
metabolism, which in part may compensate for the SR-BI defi-
ciency. In addition it is important to mention that the SR-BI att
mice are maintained in a mixed BALB/cByJ 3 129 Sv strain back-
ground.11 This may be important, too, because BALB mice are
characterized by a low cholesterol gallstone prevalence when chal-
lenged with a lithogenic diet.4
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Promoter Polymorphism of the CD14 Endotoxin Receptor Gene and Primary Biliary Cirrhosis
To the Editor:
We have read with interest the recent work by Jarvelainen et al.1
The investigators reported that the C(-159)T promoter polymor-
phism of the CD14 endotoxin receptor gene, which was found to
confer increased expression of CD14,2 may be associated with the
risk and severity of alcohol-induced liver disease. Because the
CD14 receptor is an important mediator for the activation of
monocytes/macrophages by endotoxins, this finding lends support
to the hypothesis that activation of Kupffer cells by gut-derived
endotoxins plays a key role in promoting pathologic liver injury in
alcohol-induced liver disease.
In general, one can speculate that bacterial endotoxins and liver-
derived CD14-positive monocytes/macrophages may contribute
more largely to the initiation and/or the progression of chronic
liver diseases. In this view, several observations strongly suggest
that enterobacterial antigens might play a crucial role in the patho-
genesis of primary biliary cirrhosis (PBC). For example, it has been
shown that serum antibodies against lipopolysaccharide (LPS), a
component of gram-negative bacteria, and lipid A (a component of
LPS), were more frequently found in patients with PBC than in
controls.3,4 Furthermore, unusual concentrations of endotoxins
were detected in the liver, bile, and peripheral blood of patients
with PBC,5,6 and parenteral administration of LPS in mice was
shown to induce portal inflammation, bile duct proliferation and
biliary epithelial cell degeneration.7 Finally, the CD14 receptor
was detected on mononuclear cells around the damaged bile ducts
in PBC.8
These observations prompted us to investigate whether the pro-
moter polymorphism of the CD14 gene could contribute to the
predisposition and the severity of PBC. For that purpose, we per-
formed a polymerase chain reaction (PCR) amplification of the
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promoter of the CD14 gene on genomic DNA extracted from
white blood cells of 30 women with PBC, as confirmed by posi-
tivity for antimitochondrial antibody and compatible liver histol-
ogy, and 27 age- and sex-matched control subjects. The C(-159)T
CD14 genotype was subsequently determined by restriction frag-
ment-length polymorphism (RLFP) analysis with endonuclease
HaeIII, as previously described.2 The CD14 allele and genotype
distributions were compared between patients and controls using
the x2 test. The relationships between the CD14 genotype and the
characteristics of the patients were assessed using the Jonckheere-
Terpstra test. There was no statistical difference between PBC
patients and controls for the CD14 allele and genotype distribu-
tions (Table 1). There was neither significant correlation between
the CD14 genotype and age, serum bilirubin level, activities of
alkaline phosphatase (AP), alanine and aspartate aminotransferases
(ALT and AST), serum albumin level, prothrombin time, platelet
count, serum IgM level, and histologic stage, as determined at the
time of diagnosis. Finally, the magnitude of changes in serum
bilirubin, AP, AST, and ALT levels assessed after 4 years of ursode-
oxycholic acid (UDCA) therapy did not differ between the three
CD14 genotypes. We conclude that, unlike alcohol-induced liver
disease, PBC does not show significant association with the
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Distributions of C(2159)T CD14 Genotypes and Alleles in




(n 5 27) P
CD14 genotypes
C/C 5 (16.7%) 6 (22.2%)
C/T 19 (63.3%) 15 (55.6%) NS
T/T 6 (20.0%) 6 (22.2%)
CD14 Alleles
C 29 (48.3%) 27 (50.0%) NS
T 31 (51.7%) 27 (50.0%)
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